Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

The consequences of President Trump's actions on drug pricing continue to play out, with Bristol Myers Squibb insisting it will charge the same in the UK for new schizophrenia drug Cobenfy as in the ...

Today's biopharmaceutical landscape demands a fundamental rethinking of outsourcing approaches that embrace collaboration, flexibility, and teams willing to meet halfway.

A wide of array of advanced controllers arrived in 2025, marked by high integration and enhanced intelligence in solutions ...

Rheumatologists share how they are using AI platforms for clinical documentation, reducing EHR time, streamlining workflows, ...

Today's biopharmaceutical landscape demands a fundamental rethinking of outsourcing approaches that embrace collaboration, flexibility, and teams willing to meet halfway.

Market is projected to grow at a CAGR of 18.5% from 2026 to 2033, according to a new report published by Verified Market Reports®. The report reveals that the market was valued at USD 2.56 Billion in ...